Sérgio Luiz Dalmora

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7230384/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of Denosumab by a Validated CZE Method and Determination of Sialic Acids by the RP–HPLC Method. Journal of Chromatographic Science, 2022, , .	1.4	1
2	Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays. Toxins, 2019, 11, 35.	3.4	7
3	Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methods. International Journal of Biological Macromolecules, 2018, 119, 96-104.	7.5	9
4	Assessment of rhIL-11 by Validated SE-LC Method and its Correlation with RP-LC and CZE Methods. Current Pharmaceutical Analysis, 2018, 14, 191-197.	0.6	0
5	Analysis of streptokinase by validated liquid chromatography methods and correlation with an <i>in vitro</i> bioassay. Journal of Separation Science, 2017, 40, 407-414.	2.5	5
6	Evaluation of recombinant human parathyroid hormone by CZE method and its correlation with in vitro bioassay and LC methods. Talanta, 2017, 162, 567-573.	5.5	11
7	Micellar Electrokinetic Capillary Method for the Analysis of Rivaroxaban and its Correlation with RP–LC Method and Bioassay. Current Analytical Chemistry, 2017, 13, .	1.2	2
8	Stability-indicating capillary zone electrophoresis method for the assessment of recombinant human interleukin-11 and its correlation with reversed-phase liquid chromatography and biossay. Talanta, 2014, 123, 179-185.	5.5	4
9	Effects of butyrate and manganese on productivity, sialylation, N-glycosylation site occupancy and biological properties of CHO-derived human thyrotropin. Journal of Biotechnology, 2014, 185, S106.	3.8	0
10	Development and Validation of a Stability-Indicating Size-Indicating Size-Exclusion LC Method for the Determination of rhIFN-α2a in Pharmaceutical Formulations. Journal of AOAC INTERNATIONAL, 2013, 96, 324-330.	1.5	1
11	Validation of a Stability-indicating RP-LC Method for the Assessment of Recombinant Human Interleukin-11 and Its Correlation with Bioassay. Analytical Sciences, 2012, 28, 215-215.	1.6	2
12	Stability-indicating capillary zone electrophoresis method for the assessment of recombinant human granulocyte-macrophage colony-stimulating factor and its correlation with reversed-phase liquid chromatography method and bioassay. Talanta, 2012, 94, 1-7.	5.5	12
13	Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells. Journal of Ethnopharmacology, 2011, 137, 856-863.	4.1	12
14	Development and Validation of a Stability-indicating Capillary Zone Electrophoretic Method for the Assessment of Entecavir and Its Correlation with Liquid Chromatographic Methods. Analytical Sciences, 2011, 27, 265-270.	1.6	4
15	Granulocyte-macrophage colony stimulating factor: Evaluation of biopharmaceutical formulations by stability-indicating RP-LC method and bioassay. Biologicals, 2011, 39, 211-216.	1.4	4
16	Validation of a Stability-Indicating RP-HPLC Method for the Determination of Entecavir in Tablet Dosage Form. Journal of AOAC INTERNATIONAL, 2010, 93, 523-530.	1.5	9
17	Determination of phenobarbital in human plasma by a specific liquid chromatography method: application to a bioequivalence study. Quimica Nova, 2010, 33, 124-129.	0.3	12
18	Development and validation of a dissolution test with reversed-phase liquid chromatography analysis for rupatadine in tablet dosage forms. Quimica Nova, 2010, 33, 1150-1154.	0.3	3

Sérgio Luiz Dalmora

#	Article	IF	CITATIONS
19	HPLC Determination of Bezafibrate in Human Plasma and its Application to Pharmacokinetics Studies. Journal of Chromatographic Science, 2010, 48, 362-366.	1.4	5
20	Determination of Fluticasone Propionate in Nasal Sprays by a Validated Stability-Indicating MEKC Method. Journal of Chromatographic Science, 2010, 48, 641-646.	1.4	11
21	Validation of a stability-indicating RP-HPLC method for the determination of entecavir in tablet dosage form. Journal of AOAC INTERNATIONAL, 2010, 93, 523-30.	1.5	1
22	Development and validation of a capillary zone electrophoresis method for assessment of recombinant human granulocyte colony-stimulating factor in pharmaceutical formulations and its correlation with liquid chromatography methods and bioassay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 2471-2476.	2.3	14
23	Validation of a Size-Exclusion LC Method and Assessment of rhEPO in Pharmaceutical Formulations by Liquid Chromatography and Biological Assay. Journal of Liquid Chromatography and Related Technologies, 2009, 32, 1392-1406.	1.0	7
24	A High-Throughput Liquid Chromatography Tandem Mass Spectrometry Method for the Comparative Determination of Fluticasone Propionate by Reversed-Phase Liquid Chromatography and Capillary Electrophoresis Methods in Pharmaceutical Nasal Sprays. European Journal of Mass Spectrometry, 2009, 15, 723-730.	1.0	10
25	Validation of a capillary zone electrophoresis method for the comparative determination of etoricoxib in pharmaceutical formulations. Journal of Separation Science, 2008, 31, 169-176.	2.5	14
26	Determination of rupatadine in pharmaceutical formulations by a validated stabilityâ€indicating MEKC method. Journal of Separation Science, 2008, 31, 3098-3105.	2.5	18
27	Validation of an RP-LC Method for the Determination of Interferon-α2a in Pharmaceutical Formulations. Journal of Liquid Chromatography and Related Technologies, 2008, 32, 370-382.	1.0	4
28	Validation of a Stability Indicating Reversed Phase LC Method for the Determination of Fluticasone Propionate in Pharmaceutical Formulations. Journal of Liquid Chromatography and Related Technologies, 2008, 31, 2113-2127.	1.0	7
29	Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Propranolol in Human Plasma and its Application to a Bioequivalence Study. Journal of Liquid Chromatography and Related Technologies, 2008, 31, 2927-2941.	1.0	7
30	Development and Validation of a Stability-indicating Micellar Electrokinetic Chromatography Method for the Determination of Ezetimibe in Pharmaceutical Formulations. Analytical Sciences, 2008, 24, 499-503.	1.6	19
31	Evaluation of the changes in hemostatic parameters induced by etoricoxib in rat model. Blood Coagulation and Fibrinolysis, 2008, 19, 254-257.	1.0	1
32	Determination of etoricoxib in human plasma using automated on-line solid-phase extraction coupled with LC-APCI/MS/MS. Quimica Nova, 2008, 31, 574-578.	0.3	8
33	Assessment of rhEPO in Pharmaceutical Formulations by a Reversedâ€Phase Liquid Chromatography Method and Bioassay. Journal of Liquid Chromatography and Related Technologies, 2007, 30, 1277-1288.	1.0	10
34	Simultaneous Determination of Nimesulide and Valdecoxib by Micellar Electrokinetic Capillary Chromatography Method. Journal of Liquid Chromatography and Related Technologies, 2007, 30, 2863-2877.	1.0	9
35	Validação de método por cromatografia lÃquida de alta eficiência para determinação da lamivudina e zidovudina em comprimidos. Quimica Nova, 2007, 30, 1225-1228. 	0.3	2
36	Simultaneous Liquid Chromatographic Determination of Ezetimibe and Simvastatin in Pharmaceutical Products. Journal of AOAC INTERNATIONAL, 2007, 90, 1566-1572.	1.5	19

#	Article	IF	CITATIONS
37	Development and Validation of a Stability-Indicating LC Method for the Determination of Rupatadine in Pharmaceutical Formulations. Chromatographia, 2007, 66, 915-919.	1.3	12
38	Avaliação de pirogênios em produtos de uso veterinário pelos testes da hipertermia em coelhos e do lisado de amebócitos do Limulus. Ciencia Rural, 2007, 37, 190-194.	0.5	1
39	Validation of an LCâ€Tandem MS/MS Method for the Determination of Etoricoxib in Human Plasma and Pharmaceutical Formulations. Journal of Liquid Chromatography and Related Technologies, 2006, 29, 123-135.	1.0	13
40	Validation of the Antifactor Xa and Antifactor IIa Assays for the Potency Assessment of Nadroparin in Pharmaceutical Formulations. Journal of AOAC INTERNATIONAL, 2006, 89, 58-64.	1.5	1
41	Validation of Liquid Chromatography and Liquid Chromatography/Tandem Mass Spectrometry Methods for the Determination of Etoricoxib in Pharmaceutical Formulations. Journal of AOAC INTERNATIONAL, 2006, 89, 1268-1275.	1.5	11
42	Validation of an RPâ€LC Method and Assessment of rhG SF in Pharmaceutical Formulations by Liquid Chromatography and Biological Assay. Journal of Liquid Chromatography and Related Technologies, 2006, 29, 1753-1767.	1.0	17
43	Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations. Il Farmaco, 2005, 60, 225-229.	0.9	6
44	Development and Validation of an RPâ€HPLC Method for the Dissolution Studies of Bisoprolol in Pharmaceutical Dosage Forms. Journal of Liquid Chromatography and Related Technologies, 2005, 28, 477-486.	1.0	7
45	Validation of the Anti-Factor Xa Assay for the Potency Assessment of Enoxaparin in Pharmaceutical Formulations. Journal of AOAC INTERNATIONAL, 2004, 87, 1305-1308.	1.5	4
46	Validation of an SECâ€HPLC Method for the Analysis of rhG SF in Pharmaceutical Formulations. Journal of Liquid Chromatography and Related Technologies, 2004, 27, 2689-2698.	1.0	11
47	Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations. Journal of AOAC INTERNATIONAL, 2004, 87, 1305-8.	1.5	0
48	Evaluation of recombinant human interferon beta 1b by liquid chromatography methods and bioassay. Brazilian Journal of Pharmaceutical Sciences, 0, 55, .	1.2	1